Tiziana Life Sciences is a NASDAQ-listed (NASDAQ: TLSA) clinical-stage biotechnology company that focuses on developing transformative therapies for neurodegenerative and lung diseases. With a mission to bring breakthrough therapies to patients, their clinical pipeline includes drug assets for conditions like Secondary Progressive Multiple Sclerosis, ALS, Alzheimer's, Crohn's Disease, and KRAS+ NSCLC. Led by a team of highly qualified executives with extensive drug development and commercialization experience, Tiziana is working towards optimizing health outcomes for patients.

They are developing transformational formulation technologies that enable alternative routes of immunotherapy, such as nasal, oral, and inhalation administrations, targeting neurodegenerative and lung diseases. Tiziana's vision is to change the way immunotherapies are currently conducted by successfully implementing these alternative routes of immunotherapies. They believe in the potential of their innovative approach to revolutionize the field.

For investors, Tiziana provides comprehensive stock information, presentations, press releases, financial information, and an investor calendar. Located at Clarendon House, 2 Church Street, Hamilton HM 11, Bermuda, you can reach them at info@tizianalifesciences. com or call +44 (0) 207 495 2379.

Discover more about their corporate strategy and browse through their corporate documents on their website. (Source: Tiziana Life Sciences website)